Skip to content
Emerging Research

Dihexa

Dihexa is a synthetic oligopeptide derived from angiotensin IV that potently enhances cognitive function by promoting synaptogenesis.

Also known as: Synaptogenic Peptide, Cognitive Enhancement & Neuroprotection

Typical Dose 0.5mg/kg
Storage Refrigerate reconstituted; store lyophilized powder away from light
How Often 1x daily

Overview

Dihexa is a synthetic oligopeptide derived from angiotensin IV that potently enhances cognitive function by promoting synaptogenesis. Originally developed at Washington State University for Alzheimer's disease, it's 7 orders of magnitude more potent than BDNF at stimulating new synaptic connections and uniquely crosses the blood-brain barrier.

Key Benefits

  • Memory Enhancement
  • Learning Acceleration
  • Cognitive Recovery

Dramatic synaptogenesis promotion, cognitive enhancement, memory improvement, neuroprotection, potential neuroregeneration. May help with Alzheimer's, TBI, and age-related cognitive decline.

Mechanism of Action

Dihexa binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at c-Met receptor, activating PI3K/AKT pathways. This promotes formation of new synaptic connections at levels 10 million times more potent than BDNF. Crosses blood-brain barrier effectively via oral or injectable routes.

Pharmacokinetics

Peak plasma concentration: 2 hrs. Elimination half-life: 12 hrs. Largely cleared by: ~2.5 days.

Research Protocols Injectable

GoalDoseFrequencyRoute
Research-Based Injectable0.5mg/kg1x dailySubcutaneous
Cognitive Enhancement8-10mg1x daily (morning)Subcutaneous
Intensive Learning10-15mg1x dailySubcutaneous
Neuroprotection5-8mgDaily or 3x weeklySubcutaneous
Maintenance5mgEvery other daySubcutaneous

Research protocols from published literature — not dosing recommendations.

Peptide Interactions

  • Semax — Compatible: Can be stacked for enhanced cognitive benefits but requires careful cycling to avoid overstimulation
  • Selank — Compatible: Synergistic cognitive and anxiolytic effects when combined, but monitor for neural overstimulation
  • BPC-157 — Compatible: No known negative interactions - different mechanisms of action
  • P21 — Use Caution: Both affect neuroplasticity strongly - avoid concurrent use without careful cycling
  • Noopept — Compatible: Some users stack for cognitive enhancement but limited safety data on combination
  • NAD+ — Compatible: Complementary mechanisms - NAD+ supports cellular energy while Dihexa promotes synaptogenesis
  • Cerebrolysin — Use Caution: Both are potent neurotrophic agents - combining may lead to excessive stimulation
  • TB-500 — Compatible: No known interactions - TB-500 focuses on tissue repair while Dihexa targets neural connections

Peptide Instructions Injectable

Supplies:

  • Pharmaceutical-grade DMSO (dimethyl sulfoxide) — required because Dihexa does not dissolve in water. DMSO is a common lab solvent used in FDA-approved injectables and is safe at these small volumes. Do NOT use industrial-grade DMSO.
  • PEG300 (polyethylene glycol 300) — used to dilute the DMSO concentrate into an injectable solution
  • Tween 80 (polysorbate 80) — helps keep the solution stable and well-mixed
  • Sterile saline (0.9% NaCl) for final dilution
  • Insulin syringes (for SubQ)
  • Alcohol swabs
  • Sterile vial

How to Reconstitute Injectable

  1. 1Dihexa does not dissolve in water or ethanol — you must use DMSO as the solvent
  2. 2For a 10mg vial: add 100 µL (0.1 mL) of pharmaceutical-grade DMSO to dissolve the powder completely
  3. 3Add 400 µL (0.4 mL) PEG300 and gently swirl until the solution is clear
  4. 4Add 50 µL (0.05 mL) Tween 80 and gently swirl until clear
  5. 5Add 450 µL (0.45 mL) sterile saline and gently swirl until clear — this gives you 1 mL total at 10 mg/mL
  6. 6The final ratio is 10% DMSO / 40% PEG300 / 5% Tween 80 / 45% saline — always add solvents in this order and make sure the solution is clear before adding the next one
  7. 7Store at 2-8°C, protected from moisture. Use within 30 days. Avoid repeated freeze-thaw cycles.
  8. 8For oral: No reconstitution needed — use capsules as provided

What to Expect Injectable

Week 1-2: Subtle cognitive changes, possible headaches. Week 2-4: Improved focus and memory formation. Week 4-8: Peak cognitive benefits, enhanced learning. Post-cycle: Effects may persist for days to weeks. Common effects: Mental clarity, faster learning. Side effects: Headaches (most common), anxiety, sleep disruption if taken late.

Side Effects & Safety

Not FDA approved - research compound only. Theoretical cancer risk via c-Met activation. No long-term human safety data available. Avoid if history of cancer. Not for pregnant/nursing women. May cause overstimulation or anxiety. Requires cycling to prevent tolerance.

Not FDA approved - research compound only. Theoretical cancer risk via c-Met activation. No long-term human safety data available. Avoid if history of cancer. Not for pregnant/nursing women. May cause overstimulation or anxiety. Requires cycling to prevent tolerance.

Community Insights

Dihexa should be stored at Oral capsules: room temperature. Injectable: requires DMSO to dissolve (Dihexa won't dissolve in water), store DMSO stock solution at 2-8°C. Always use pharmaceutical-grade DMSO..

Molecular Information

Molecular Weight 504.7 Da
Type Oligopeptide
Sequence Hexanoyl-Tyr-Ile-Ahx-NH2 (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide)

References

  1. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway Sun X, Deng Y, Li W, et al. · International Journal of Molecular Sciences 2021
  2. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies Ho JK, Nation DA · Neuroscience & Biobehavioral Reviews 2018
  3. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases Wright JW, Kawas LH, Harding JW · Progress in Neurobiology 2015
  4. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system Benoist CC, Kawas LH, Zhu M, et al. · Journal of Pharmacology and Experimental Therapeutics 2014
  5. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents McCoy AT, Benoist CC, Wright JW, et al. · Journal of Pharmacology and Experimental Therapeutics 2013

Research reference only. Not medical advice.